# Milestone Scientific Inc.: Form 10-Q for the period ended Jun 30, 2010

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2010-08-10
- Accepted by EDGAR: Aug 10, 2010, 16:27 ET
- Period: 2010-06-30
- Accession: 0000950123-10-075649
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000095012310075649/c04564e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000095012310075649/

## Management's discussion and analysis

As filed, 37,502 characters.

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements. See “Risk Factors” on Part II. ITEM 1A of this Form 10-Q.

“Milestone Scientific,” the Milestone logo, “The Wand,” “The Safety Wand,” “*CompuMed®,” “CompuFlo®,” “CompuDent®,” “*DPS Dynamic Pressure Sensing” and “*STA Single Tooth Anesthesia System®”* are registered trademarks; and “C-CLAD” is a trademark of Milestone Scientific, Inc.

### OVERVIEW

In 2010, Milestone has remained focused on advancing efforts to achieve our two primary objectives; those being:

- Optimizing our tactical approach to product sales and marketing in order to materially increase penetration of the global dental markets with our proprietary, patented Computer-Controlled Local Anesthesia Delivery (C-CLAD) solution, the *STA Single Tooth Anesthesia System®*; and
- Identifying and pursing strategic collaborations with third parties to jointly develop new products utilizing our patented *CompuFlo®* system’s pressure force technology for novel new medical applications.

### STA Single Tooth Anesthesia System® Awards — Industry Recognition

Since its market introduction in the spring of 2007, the *STA Single Tooth Anesthesia System®* has received very positive reviews and awards from the dental industry. In April 2008, *Medical Device & Diagnostic Industry* magazine distinguished the *STA Single Tooth Anesthesia System®* as a 2008 Medical Design Excellence Award winner in the “Dental Instruments, Equipment and Supplies” product category. Of the 33 products to receive this coveted award, the *STA Single Tooth Anesthesia System®* was one of only two winning products that serve dental practitioners.

In July 2008, noted industry publication *Dentistry Today* featured the *STA Single Tooth Anesthesia System®* as one of the “Top 100 Products in 2008,” helping to promote broader recognition of the instrument and validating its value proposition for dentists and patients alike. The *STA Single Tooth Anesthesia System®* went on to be named by *Dentistry Today* as one of the “Top 100 Products” for 2009 and 2010, marking three consecutive years the instrument has achieved this industry distinction.

In December 2008, the *STA Single Tooth Anesthesia System®* was recognized as one of the dental industry’s best technological innovations, winning a “Townie Choice Award” from *Dentaltown Magazine* in the category “Anesthetics: Technique System”. This marked the second consecutive year that Milestone won a “Townie Choice Award”; in 2007, we won the same award for our *CompuDent®/The Wand®* instrument. Also in December 2008, our *STA Single Tooth Anesthesia System®* was named as a *Dental Products Report “*Top 100 2008 Product of Distinction”. Each year, *DPR* spotlights the year’s Top 100 products. Of these 100 products, 50 are the ones most often inquired about by *DPR’*s readers via an online and Product Information Card reader service program. The other 50 represent “New Classics,” which recognize both old and newer products and categories chosen by *DPR’s* editorial staff for their “perceived impact on driving innovation or helping to establish a new, higher standard of care for patients.” The *STA Single Tooth Anesthesia System®* was recognized as a “New Classic” in the Technology category.

In 2009 the *STA Single Tooth Anesthesia System®* was named by *Dentistry Today* as one of the “Top 100 Products” for the second time and again in 2010, marking three consecutive years the instrument has achieved this notable industry distinction.

In June 2010, the *STA Single Tooth Anesthesia System®* won further industry distinction, honored as one of only 13 stand-out dental technologies to receive the Pride Institute’s “Best of Class” Technology Award for 2010.

#### Second Annual Symposium on C-CLAD ®

In addition to winning noted acclaim among leading dental publications, our award winning *STA Single Tooth Anesthesia System®* has also been gaining the support of many of the world’s leading dental practitioners and key opinion leaders. In February 2008, we hosted the First International Computer-Controlled Local Anesthesia Delivery (*C-CLAD®)*

The Symposium in New Orleans, welcomed a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the science, knowledge and art of *C-CLAD* in dentistry. The forum yielded a number of ideas on how we can integrate the *STA Single Tooth Anesthesia System®* not only into dental school curricula, but also extends messaging regarding its many unique benefits to the dental community and patients alike.

On May 1 through May 3, 2009, we hosted the Second International Annual Symposium on *C-CLAD* in Amelia Island, Florida. Stanley Malamed, DDS, Professor of Anesthesia & Medicine at the University of Southern California, School of Dentistry, again served as Chairman of the invitational event. With attendance triple that of 2008, the 2009 Symposium covered a broad range of *C-CLAD* related topics including:

- The History of *C-CLAD*
- Treating with Connection
- Heart Rate Study
- *STA Single Tooth Anesthesia System®:* Compassionate Care in the 21st Century
- Injection Advances and Challenges
- Physiologic and Clinical Characteristics of PDL Anesthesia Delivered by a High Pressure Hand piece and a Computerized Device
- The *STA Single Tooth Anesthesia System®* for Tots and Teens
- Computerized Local Anesthesia in Dentistry: A Review
- Today’s Technology
- Managing a Successful Dental Practice: Why People Keep Coming Back
- *STA Single Tooth Anesthesia System® —* The Dental School’s Perspective
- Futuristic Vistas: The Dentist/Hygienist Partnership

In 2010, we have broadly distributed more than 30,000 copies of a comprehensive monograph reflecting the topics discussed at the 2009 Symposium and a consensus on the attendees’ attitudes, ideas and suggestions relating to promoting global industry adoption of *C-CLAD* technologies as the new standard of care for administering dental injections.

### STA Single Tooth Anesthesia System® Growth

Since its market introduction in early 2007, the *STA Single Tooth Anesthesia System®,* along with prior generations of Milestone’s *C-CLAD* products (*CompuDent®/The Wand®* instruments) have been used to deliver tens of millions of safe, effective and comfortable injections. The *STA Single Tooth Anesthesia System®* has been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the instrument is proving to be a valuable and beneficial tool that is positively impacting the practice of dentistry worldwide. The utility and value of the *STA Single Tooth Anesthesia System®* is perhaps best summarized by Dr. Joe Blaes, who wrote in the December 2008 edition of *Dental Economics, “*I tried the *STA Single Tooth Anesthesia System®* and my patients absolutely love it. This is a no brainer — go get one ASAP!”

### Global Distribution Network

The *STA Single Tooth Anesthesia System®* and related handpieces are marketed to the dental industry in the United States and Canada by many of the nation’s leading dental supply companies.

On the global front, we also have granted exclusive marketing and distribution rights for the *STA Single Tooth Anesthesia System®* to select dental suppliers in various international regions in Asia, Africa and Europe.

In April 2009, we signed an Exclusive Distribution and Marketing Agreement with China National Medicines Corporation, d/b/a Sinopharm, which is China’s largest domestic manufacturer, distributor and marketer of pharmaceuticals and importer of medical devices and the country’s largest domestic distributor of dental anesthetic carpules to the Chinese dental industry. Prior to the end of 2009, China National Medicines issued Milestone a blanket purchase order for 12,000 *STA Single Tooth Anesthesia Systems®* to be delivered over 36 months, thereby marking the Company’s initial penetration into China’s emerging dental market.

According to a report published by the U.S. Department of Commerce, titled “China’s Emerging Markets: Opportunities in the Dental and Dental Lab Industry,” China’s dental market lags behind other healthcare services and has largely been neglected in the past. In fact, CS Market Research reports that “of China’s 1.3 billion plus population, 50% of the adults and 70% of the children are estimated to have decayed tooth problems, and over 90% have periodontal disease.” However, with increasing affluence of the Chinese population, as well as increasing attention towards personal care, demand for dental services has been growing. Market research firm Freedonia agrees, noting that demand for dental products in China is expected to climb to 21.5 billion RMB (US$3.15 billion) by 2012, due primarily to escalating personal income levels and government programs promoting awareness of the benefits of good oral care.

Shortly before the end of the second quarter of 2009, we announced that we were refining our international marketing strategy to gain greater access to and penetration of the international dental markets for the *STA Single Tooth Anesthesia System®*, the *CompuDent®* instrument and related disposable hand pieces. The new sales strategy provides for increasing hands-on oversight and support of our existing international distribution network, while also attracting new distributors throughout Europe, Asia and South America. To assist in this endeavor, Milestone named Shaul Koren, founder and CEO of Istrodent Pty Ltd AB and one of our strongest sales allies outside of the U.S., as our new International Sales Director. In collaboration with senior management, Mr. Koren will help manage product sales for us in all markets outside of North America.

In the second quarter of 2010, Milestone appointed Dale Johnson as Director of International Distribution, who is now responsible for overseeing the Company’s network of independent dental distributors. Subsequent to the end of the quarter, Milestone named Marvin Terrell as Director of Domestic Distribution, a newly created position responsible for all facets of domestic distribution and marketing of Milestone’s dental products in the U.S. and Canada, including serving as the chief liaison between the Company and the dental supply companies who comprise its domestic distribution network.

### Segmented Sales Performance

The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

| DOMESTIC | Three Months Ended June 30, 2010 |  | 2009 |  |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $332,392 | 26.4% | $527,725 | 37.5% |
| Handpieces | 908,626 | 72.2% | 861,991 | 61.2% |
| Other | 17,838 | 1.4% | 18,620 | 1.3% |
| Total Domestic | $1,258,856 | 100.0% | $1,408,336 | 100.0% |
| **INTERNATIONAL** |  |  |  |  |
| Instruments | $1,491,972 | 76.1% | $288,180 | 45.8% |
| Handpieces | 463,854 | 23.7% | 338,378 | 53.8% |
| Other | 3,987 | 0.2% | 2,008 | 0.4% |
| Total International | $1,959,813 | 100.0% | $628,566 | 100.0% |
| **DOMESTIC/INTERNATIONAL ANALYSIS** |  |  |  |  |
| Domestic | $1,258,856 | 39.1% | $1,408,336 | 69.1% |
| International | 1,959,813 | 60.9% | 628,566 | 30.9% |
| Total Product Sales | $3,218,669 | 100.0% | $2,036,902 | 100.0% |

| DOMESTIC | Six Months Ended June 30, 2010 |  | 2009 |  |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $583,989 | 23.7% | $1,054,138 | 36.5% |
| Handpieces | 1,838,610 | 74.6% | 1,793,801 | 62.1% |
| Other | 41,228 | 1.7% | 38,892 | 1.4% |
| Total Domestic | $2,463,827 | 100.0% | $2,886,831 | 100.0% |
| **INTERNATIONAL** |  |  |  |  |
| Instruments | $1,840,263 | 55.5% | $547,984 | 40.4% |
| Handpieces | 1,470,173 | 44.3% | 801,780 | 59.2% |
| Other | 6,984 | 0.2% | 5,126 | 0.4% |
| Total International | $3,317,420 | 100.0% | $1,354,890 | 100.0% |
| **DOMESTIC/INTERNATIONAL ANALYSIS** |  |  |  |  |
| Domestic | $2,463,827 | 42.6% | $2,886,831 | 68.1% |
| International | 3,317,420 | 57.4% | 1,354,890 | 31.9% |
| Total Product Sales | $5,781,247 | 100.0% | $4,241,721 | 100.0% |

The Company earned gross profits of 64% and 58% in for the three months ended June 30, 2010 and 2009, respectively. However, our revenues and related gross profits have not been sufficient to fully support the expansion of our business efforts, including a new product introduction and research and development expenses. Although the Company anticipates expending funds for research and development in 2010, these amounts will vary based on the operating results for each quarter. The Company has incurred operating losses since its inception. The Company is actively pursuing the generation of sustainable positive cash flows from operating activities through increases in revenue, assessment of current contracts and current negotiations and reduction in operating expenses.

### New Product Development and Commercialization Utilizing CompuFlo® System Technology

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. According to market research firm Business Insights, “The global market grew from $15 billion to $40 billion during 2000—2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.” Moreover, industry analysts agree that as patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. It appears that pharma company decision makers are realizing that new drug product success no longer only depends on the medication itself, but also on achieving a patient-friendly form of delivery.

Central to Milestone’s robust IP portfolio, currently comprised of 25 issued patents, is its FDA-approved *CompuFlo®* system for the precise delivery and aspiration of all medicaments. Milestone’s patented *CompuFlo®* system and *DPS Dynamic Pressure Sensing®* technology are revolutionary technologies that are relevant for the entire category of subcutaneous drug delivery injections and fluid aspiration — enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the existing technologies.

The negative side effects possible when using the manual hypodermic syringe are well documented in the medical and dental literature, and include tissue damage, transient or permanent paralysis, subjective pain response, post-operative complications, and the risk of medical emergencies, which in certain circumstances can result in a patient fatality. Patient pain and tissue damage are a direct physical result of a clinician’s inability to accurately control a wide range of variables when using the manual syringe.

**In contrast, the technical advantages of the** ***CompuFlo®*** **system with** ***DPS Dynamic Pressure Sensing®*** **technology are numerous and dramatic**. They include precise controlling and monitoring of **all** critical variables during drug delivery, including:

- a true “painless” experience for all injections
- eliminates disruptive injection behavior
- site specific targeting
- controlled needle exit-pressure
- precise flow rate and drug volumes
- patient treatment documentation
- superior ergonomics
- elimination of needle deflection (causing missed injections, lost time and anxiety )
- advanced tactile needle control
- precision fluid metering

The use of Milestone’s technology also empowers the clinician to receive real-time continuous feedback relating to the local tissue conditions during the injection process. This real-time feedback enables the accurate differentiation and identification of specific tissues types and anatomical locations, making subcutaneous drug delivery safer, easier and more effective, thereby fundamentally transforming what formerly was an “art” into a “science.”

Recognized as a world leader in advanced computer-controlled injection technologies, Milestone has spent over a decade developing and perfecting its portfolio of technologies that eliminate pain and enable unequaled precision that can be applied to a wide array of subcutaneous injections routinely used in the practice of Medicine and Dentistry. Moreover, none of Milestone’s *C-CLAD* injection products look like a syringe or feel like a syringe, and they perform far better than an antiquated manual syringe, resulting in a much enhanced experience for both the patient, the practitioner and the business of dentistry.

Based on an independent 2006 study, the number of potential applications for the *CompuFlo®* technology stands at more than 700. Due to the sizable number of product development opportunities within the medical arena for the technology, Milestone created an internal review committee to assess and analyze the opportunities in a variety of medical sectors. Consequently, the Company has elected to focus on those medical uses of the *CompuFlo®* system which have shown to be most promising for obtaining a return on investment while simultaneously representing new product introductions that will have the greatest impact on patients and the medical profession. Areas of initial interest include developing *CompuFlo®*-based injection/aspiration systems for use in Epidurals, Intra-Articular Injections, Self-Administered Injections, Neurosurgery, Ophthalmic surgery and Derma Filler/Cosmetic surgery.

It should be noted that the *CompuFlo®* system is embedded in an FDA-approved prototype. This technology is currently commercially available in the *STA Single Tooth Anesthesia System®*, which is being sold worldwide in the dental market. Over 40 million patient injections have been given with Milestone’s technologies to date.

Milestone’s technological innovations have been tried and proven by healthcare providers with over 50 publications validating the efficacy and safety in a variety of medical and dental injection applications. It is anticipated that future devices that are developed utilizing the *CompuFlo®* system will only require a basic 510K approval from the FDA, thus minimizing development cost and time to market.

### Intellectual Property

In August 2009, we were issued a Notice of Allowance by the U.S. Patent and Trademark Office for its U.S. patent application directed to the use of its disposable hand piece for fluid administration. Our award-winning handpiece is an instrument currently utilized in conjunction with the Company’s *STA Single Tooth Anesthesia System®, the CompuDent®* instrument and the *CompuMed®* instrument.

In September 2009, the U.S. Patent and Trademark Office issued a Notice of Allowance for our U.S. patent application, titled “Computer Controlled Drug Delivery System with Dynamic Pressure Sensing.” This intellectual property represents one of the key technological components of our product development strategy relating to the development of advanced computer-controlled injection products for specific applications in the medical industry — most notably intra-articular injections and epidurals.

During the second quarter of 2010, Milestone was issued a Notice of Allowance by the U.S. Patent and Trademark Office for its U.S. patent application, titled “Self-Administration Injection System.” Milestone’s innovative computer-controlled drug delivery platform has been designed to reduce the anxiety and pain of self-administration of medications for the rapidly expanding home-use market. The computer-controlled self-administration system provides a less threatening, virtually painless means for patients to safely self-administer in-home a variety of injections.

To date, we have been awarded a total of 25 U.S. utility and design patents relating to our *C-CLAD* technologies.

### Summary of Significant Accounting Policies, Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

#### Accounts Receivable

The realization of Accounts Receivable will have a significant impact on the Company. Consequently, Milestone estimates losses resulting from the inability of its customers to make payments for amounts billed. The collectability of outstanding amounts is continually assessed.

#### Inventories

Inventory costing, obsolescence and physical control are significantly important to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

#### Impairment of Long-Lived Assets

The long lived assets of the Company, principally patents and trademarks are the base features of the business. We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

#### Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to our domestic distributors on the date of arrival of the goods at the customer’s location as shipments are FOB destination. Shipments to our international distributor are FOB our warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Our only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective instrument is returned within the warranty period.

### Results of Operations

The consolidated results of operations for the three and six months ended June 30, 2010 compared to the same three and six month period in 2009 reflect our focus and development on the *STA Single Tooth Anesthesia System®* , as well as continuing efforts on identifying collaborative partners for new product development utilizing our *CompuFlo®* technology.

The following table sets forth for the periods presented statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

|  | Three Months Ended June 30, 2010 |  | 2009 |  | Six Months Ended June 30, 2010 |  | 2009 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products sales, net | $3,218,669 | 100% | $2,036,902 | 100% | $5,781,247 | 100% | $4,241,721 | 100% |
| Cost of products sold | 1,161,847 | 36% | 862,741 | 42% | 2,062,558 | 36% | 1,779,291 | 42% |
| Gross Profit | 2,056,822 | 64% | 1,174,161 | 58% | 3,718,689 | 64% | 2,462,430 | 58% |
| Selling, general and administrative expenses | 1,778,193 | 55% | 1,753,237 | 86% | 3,319,896 | 57% | 3,482,052 | 82% |
| Research and development expenses | 79,736 | 2% | 32,347 | 2% | 168,200 | 3% | 99,969 | 2% |
| Total operating expenses | 1,857,929 | 57% | 1,785,584 | 88% | 3,488,096 | 60% | 3,582,021 | 84% |
| Income (loss) from operations | 198,893 | 6% | (611,423) | -30% | 230,593 | 4% | (1,119,591) | -26% |
| Other income — interest & expense | (18,533) | -1% | (45,119) | -2% | 33,689 | 1% | (98,592) | -2% |
| Net income (loss) | $180,360 | 5% | $(656,542) | -32% | $264,282 | 5% | $(1,218,183) | -28% |

### Three months ended June 30, 2010 compared to three months ended June 30, 2009

Total revenues for the three months ended June 30, 2010 and 2009 were $3,218,669 and $2,036,902, respectively. The total increase in product sales of $1,181,767, or 58%, in 2010 over 2009 is primarily the result of the continued *STA Single Tooth Anesthesia System®* product sales growth in the China market. Domestic *STA Single Tooth Anesthesia System®* instrument sales decreased $210,378 in 2010 over 2009. This notable decrease is due to the reduction in advertising and the sales force in 2010 over 2009, as management implements a new sales strategy in the U.S. In the domestic market, handpiece sales increased by $46,635, or 5.4%. On the international front, total revenue aggregated $1,959,813 in 2010, a 212% increase over 2009. All of this increase was due to the shipment of instruments and handpieces to China. International instrument sales increased in the second quarter of 2010 over 2009 by $1,203,792, or 418%. Internationally, handpieces increased by $125,476, or 37% due to shipment of training and demonstration handpieces to China.

Cost of products sold for the three months ended June 30, 2010 and 2009 were $1,161,847 and $862,741, respectively. The $299,106, or 35%, increase is attributable to an increase in sales volume.

For the three months ended June 30, 2010, Milestone generated a gross profit of $2,056,822, or 64%, as compared to a gross profit of $1,174,161, or 58%, for the three months ended June 30, 2009. The total increase in gross profit dollars of $882,661 is due to an increase in sales volume, while the gross profit percentage increase is due to a reduction in the manufacturing costs for the *STA Single Tooth Anesthesia System®* instruments in 2010.

Selling, general and administrative expenses for the three months ended June 30, 2010 and 2009 were $1,778,193 and $1,753,237, respectively. The $24,956, or 1.4%, net increase is described in the following sections of this paragraph. Although the Company continues to focus on expenses, the 2010 second quarter increase of $24,956 is a net of reductions in Marketing Expenses of $291,464, Sales Expenses of $33,726 and Salary Expense of $60,356, offset by increase General and Administrative (G&A) Expenses of $410,502. Expense reduction in Marketing Expense is principally due to foregoing the Spring C-CLAD Symposium and other Marketing Consulting (savings of approximately $205,000) and reduction in the media spend of approximately $69,000. In the category of G&A Expenses, 2010 quarterly expenses increased $156,162 for an International Sales Commission (China $64,800 and other countries $91,362) based on increased international sales, $81,038 increase in Royalty payments, $37,742 increase in International Travel Expense, Recruiting and Consulting Expenses of $66,979 (recruiting a Director, International Business in April 2010, $30,000) and an increase in the CEO’s Bonus of $55,332.

Research and development expenses for the three months ended June 30, 2010 and 2009 were $79,736 and $32,347 respectively. The increase of $47,389 is partially due to increased expenditures for new medical devices development.

The income from operations for the three months ended June 30, 2010 was $198,893 as compared to a loss from operations for the three months ended June 30, 2009 of $611,423. The difference of $810,316 or 133%, increase in income from operations is explained above.

Interest income of $112 was earned for the three months ended June 30, 2010 compared to $742 for the same period in 2009.

Interest expense was $17,946 and amortization of debt issuance was $699 relating to the long term note payable for the second quarter of 2010 compared to interest expense of $37,986 and amortization of debt issuance expense of $7,875 for the same quarter in 2009. The decrease in interest expense $20,040 is due to the conversion of the Line of Credit Note in December 2009 (as discussed in Note 5).

For the reasons explained above, net income for the three months ended June 30, 2010 was $180,359 as compared to a net loss of $656,542 for the three months ended June 30, 2009. The $836,902, or 127%, increase in net income is primarily a result of the increase in sales and gross margin dollars, offset by one time decreases in market consulting costs and increases in other selling, general and administrative expenses.

### Six months ended June 30, 2010 compared to the six months ended June 30, 2009

Total revenues for the six months ended June 30, 2010 and 2009 were $5,781,247 and $4,241,721, respectively. Total revenues increased by $1,539,525, or 36%. All of this increase in revenue was generated by shipments to China Contributing to this increase was *STA Single Tooth Anesthesia System®* instruments sales of $763,707 and an increase in *STA Single Tooth Anesthesia System®* handpiece sales of $659,135. *CompuDent®* instrument sales increased by $58,423 and *CompuDent®* handpiece sales increased by $54,067. International revenue increased $1,962,530, or 145%, as compared to the 2009 period. Domestic product revenue decreased $423,004 in 2010, or 15%, the notable decrease in due to the reduction in advertising and direct sales force expenses in 2010 over 2009, as management implements a new sales strategy in the U.S. Domestic disposable handpiece sales increased by $44,809, or 2%, and international disposable handpiece sales increased $668,393, or 83%.

Gross profit for the six months ended June 30, 2010 and 2009 was $3,718,689, or 64%, and $2,462,430, or 58%, respectively. Gross profit dollars in the first six months of 2010 increased by $1,256,259, 51% due to an increase in sales volume and gross profit percentage in 2010 over 2009. The gross profit percentage increase is due to a reduction in the manufacturing costs for the *STA Single Tooth Anesthesia System®* instruments in 2010.

Selling, general and administrative expenses for the six months ended June 30, 2010 and 2009 were $3,319,896 and $3,482,052, respectively. The decrease of $162,156, or 4.7%, is primarily attributable to a net reduction in Marketing Expenses of $575,853, Sales Expenses of $69,791 and Salary Expenses of $100,202, offset by increase in General and Administrative (G&A) Expense of $603,475. Sales and marketing expense decreased by $648,644 is principally due to foregoing the Spring C-CLAD Symposium and other Marketing Consulting (savings of approximately $357,000), reduction in the media spend of approximately $149,000, a net reduction of printing ($77,503) and a reduction in sales commissions ($21,469) and domestic sales travel expenses ($50,429) for the period ending June 30, 20010. This aggregate decrease is attributable to management’s implements of a new sales strategy in the U.S. General and administrative expenses increased a net of $603,475. Expense increases in this category that are directly related to sales volume increases was $476,928. International sales commissions $294,112 (China $64,800 and other countries $229,312), international travel $57,741 and royalty payments $125,075. Stock based compensation expense increased by $51,882. Recruiting and Consulting Expenses of $94,127 (recruiting a Director, International Business in April 2010, $30,000) and a decrease in salary expenses of $100,202 due to a reduction in salesman staffing.

Research and development expenses for the six months ended June 30, 2010 and 2009 were $168,200 and $99,969, respectively. The increase of $68,231 is due to increased expenditures for the development of new medical devices ($25,477) and foreign language enhancements for our *STA Single Tooth Anesthesia System®* instruments ($26,000).

Other Income includes $61,916 in 2010. This represents the balance of the sale of tax credits under the New Jersey Technology Tax Certificate Program.

Interest income of $460 was earned for the six months ended June 30, 2010 compared to $2,547 for the same period in 2009.

Interest expense of $27,288 as of June 30, 2010 decreased $58,101, or 68%, over the same period in 2009. The decrease in interest expense is due to the conversion of the Line of Credit Note in December 2009 (as discussed in Note 5).

For the reasons explained above, net income for the six months ended June 30, 2010 increased to $264,282, a positive increase of $1,482,464, or 121.7%, over the net loss for the six month period ended June 30, 2009.

Working capital as of June 30, 2010 is $2,311,435. Current assets increased by $1,857,400 in categories accounts receivable ($740,525), inventory ($460,289) and advances to a contract manufacturer ($838,768) offset by a reduction in cash of $209,540 from December 31, 2009.

### Liquidity and Capital Resources

As of June 30, 2010 we had cash and cash equivalents of $819,589 and working capital of $2,311,435, an increase in working capital from December 31, 2009 of $685,362. Milestone generated net income of $264,281 and incurred a net loss of $1,218,183 for the six months ended June 30, 2010 and 2009, respectively. There was a negative cash flow from operating activities of $129,532 and $195,391 for the six months ended June 30, 2010 and June 30, 2009, respectively.

For the six months ended June 30, 2010, our net cash used in operating activities was $129,532. This was attributable primarily to a net income of $264,282, adjusted for noncash items of $334,912, principally common stock and options issued for compensation, consulting and vendor services and changes in operating assets and liabilities of $728,726. The changes in operating assets and liabilities are due to building up of inventory and the increase in advances for the expected sales growth in the third and fourth quarter of 2010.

The Company’s increase in current asset of $1,857,400 is primarily due to a build up of inventory ($460,289) and increase in advances to contract manufacturer ($881,353) principally for the 12,000 STA System instruments purchase order form China and a net increase in accounts receivable ($740,525). These increases are anticipated to continue in order to deliver the instruments on time and complete per the purchase order.

On a related basis, current liabilities increased by $1,172,038 of which $1,098,551 relates to the advance to contract manufactures and the purchases of handpieces for the China purchase order. Both the advance and payable to contract manufacturer are expected to continue to exist until the 12,000 instrument order is delivered to the distributor.

For the six months ended June 30, 2010, Milestone used $80,008 in investing activities. This was primarily attributable to $56,739 of legal fees related to new patent application. Capital expenditures of $23,269 were primarily for the leasehold improvement in the Livingston, New Jersey office.

As of June 30, 2010 and December 31, 2009, Milestone had recorded on the Balance Sheet a long term note payable of $450,000 from a stockholder.

The Company is actively pursuing the generation of sustainable positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. If the Company is unable to maintain positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve sustainable positive operating cash flows or that traditional capital can be raised on terms and conditions satisfactory to the Company. If additional capital is required and cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company’s operating results.

The Company’s historical losses — raises substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

## Controls and procedures

As filed, 1,258 characters.

The Company’s management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of June 30, 2010 are effective to ensure that information required to be disclosed in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the Company’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

Filed Aug 10, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-075649. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
